Oregon Prescription Drug Affordability Board June, 18, 2025 Meeting Highlights presented by OCAP

Which Drugs Made the List? 16 prescription drugs and 7 insulin products selected for affordability review 4 orphan drugs (e.g., Humira, Botox) removed due to current statute Selection focused on cost (net payer) and patient volume

What's Powering the Decisions? Data from 11 commercial insurers (net cost) APAC data (gross cost incl. Medicare/Medicaid) New PDAB dashboard features: Drug lookup NDC info Plan designs

Looking Ahead Next PDAB Meeting: July 16, 2025 @ 9 AM Tune in for the start of affordability reviews! Insulin review scheduled for later in 2025 Public hearing on PBM rulemaking: June 23 Board member recruitment extended to July 7

At last week's meeting, the Oregon Prescription Drug Affordability Board (#PDAB) reviewed data, approved a 16-drug review list, and discussed #insulin pricing. Learn more in the slides →

Next meeting: July 16, 2025 at 9 AM.

#OregonPDAB #DrugAffordability #HealthPolicy #InsulinAccess #OCAP